Hypothesis

Age‑related NAD+ decline does not merely impair mitochondrial respiration; it simultaneously limits α‑ketoglutarate (α‑KG) production by reducing glutamine uptake, thereby suppressing KDM6 demethylase activity and allowing PRC2‑mediated H3K27me3 accumulation at glycolytic gene promoters. This coordinated epigenetic shift lowers metabolic output while preserving H3K4me3 at stress‑response loci, creating a tumor‑suppressive but energetically constrained state. Restoring both NAD+ and α‑KG in aged organisms will reactivate glycolysis and, paradoxically, increase tumorigenesis, proving that the NAD+ drop is an adaptive downgrade rather than passive damage.

Mechanistic Basis

NAD+ is a obligate cofactor for SIRT1 deacetylase, which deacetylates and activates GCN5, a histone acetyltransferase that antagonizes PRC2 activity at metabolic promoters. When NAD+ falls, SIRT1 activity wanes, GCN5 remains acetylated and less active, tipping the balance toward PRC2‑mediated H3K27me3 deposition. In parallel, NAD+ shortage reduces SLC1A5‑mediated glutamine import, limiting the TCA‑cycle flux that generates α‑KG, the essential cofactor for KDM6 demethylases that erase H3K27me3. Loss of KDM6 activity lets H3K27me3 spread from peaks into inter‑genic regions, silencing glycolytic enzymes such as Pfkp and LDHA. Meanwhile, H3K4me3 marks at promoters of DNA‑damage response genes remain stable because their maintenance relies on SETD1 complexes that are NAD+ independent. Thus, the cell experiences a dual hit: reduced acetylation‑driven antagonism of PRC2 and diminished demethylase‑driven removal of repressive marks, locking chromatin into a low‑metabolism, high‑repressive configuration.

Predictions

1. In aged muscle, NAD+ supplementation alone will raise SIRT1 activity and partially restore H3K4 acetylation but will not significantly lower H3K27me3 at glycolytic loci unless α‑KG is also replenished.
2. Combined NAD+ (e.g., nicotinamide riboside) and cell‑permeable α‑KG (dimethyl‑α‑KG) treatment will decrease H3K27me3 enrichment at Pfkp and LDHA promoters, increase glycolytic flux (measured by ECAR), and elevate lactate production.
3. The same combined treatment will increase the incidence of spontaneous tumors or accelerate growth of transplanted oncogenic clones in aged mice relative to NAD+‑only or vehicle controls.
4. Inhibiting KDM6 (with GSK‑J4) will block the metabolic rescue caused by NAD+ + α‑KG, confirming that demethylase activity is required for the glycolytic rebound.

Experimental Design

• Animals: 24‑month‑old C57BL/6J mice, both sexes, n=10 per group.
• Groups: (1) Vehicle, (2) NAD+ precursor (NR 400 mg/kg/day), (3) α‑KG ester (DM‑α‑KG 500 mg/kg/day), (4) NAD+ + α‑KG combination, (5) Combination + KDM6 inhibitor (GSK‑J4 50 mg/kg/day).
• Duration: 8 weeks.
• Readouts: ChIP‑qPCR for H3K27me3 and H3K4me3 at Pfkp, LDHA, and p21 promoters; Seahorse glycolysis assay; serum lactate; MRI‑based tumor surveillance; histological scoring of any neoplasms.
• Statistical test: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Potential Outcomes

If the combination group shows a significant drop in H3K27me3 at metabolic genes, a rise in glycolysis, and a higher tumor burden compared with NAD+‑only or α‑KG‑only groups, the hypothesis is supported: NAD+ decline is a regulated downgrade that couples metabolic restraint to tumor suppression. If NAD+ restoration alone rescues metabolism without affecting cancer risk, or if the combination fails to alter H3K27me3 or tumorigenesis, the hypothesis is falsified, suggesting that NAD+ loss acts primarily through independent pathways.

This framework directly links the observed opposing H3K27me3/H3K4me3 landscapes in aging and cancer to a nutrient‑sensing epigenetic switch, offering a clear, falsifiable test of whether the cell’s "budget cut" is an active strategy to limit proliferative potential at the expense of energetic vigor.